Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

2013572 citationsJournal Articlebronze Open Access

Authors

María‐Victoria Mateos · Centro de Investigación del Cáncer

Miguel‐Teodoro Hernández

Abstract

Early treatment for patients with high-risk smoldering myeloma delays progression to active disease and increases overall survival. (Funded by Celgene; ClinicalTrials.gov number, NCT00480363.).

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Ubiquitin and proteasome pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 5, pp. 438-447

DOI: 10.1056/nejmoa1300439

Field-Weighted Citation Impact: 37.99